NCT03601910View on ClinicalTrials.gov

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

PHASE1UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

September 21, 2018

Study Completion Date

November 9, 2018

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

D308 10mg Tab.

D308 10mg Tab.1T single oral administration under fasting condition

DRUG

CKD-380 10mg Tab.

CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition

Trial Locations (1)

Unknown

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY